Research progress on the regulation mechanisms of iron metabolism in anemia of chronic disease.
- Author:
Hai-Chao MI
1
;
Fang CUI
2
;
Yu-Tao DU
1
;
Ruo-Tong WANG
1
;
Rui ZHANG
1
;
Min SHI
3
Author Information
1. Department of Clinical Laboratory, Second Hospital of Hebei Medical University, Shijiazhuang 050000, China.
2. Department of Electron Microscopy Laboratory Centre, Hebei Medical University, Shijiazhuang 050017, China.
3. Department of Clinical Laboratory, Second Hospital of Hebei Medical University, Shijiazhuang 050000, China. sm8344@sina.com.
- Publication Type:Review
- MeSH:
Anemia;
Anemia, Iron-Deficiency/pathology*;
Chronic Disease;
Hepcidins;
Humans;
Iron/metabolism*
- From:
Acta Physiologica Sinica
2022;74(4):639-647
- CountryChina
- Language:Chinese
-
Abstract:
Anemia of chronic disease (ACD), complicated by various chronic inflammatory diseases, is the second most prevalent type of anemia after iron deficiency anemia in the world. ACD significantly reduces the life quality of patients with chronic diseases, and represents an independent poor prognostic factor in certain chronic diseases. A large body of studies has demonstrated that most of anemia is related to abnormal iron metabolism. In the past decade, hepcidin, as a key factor in regulating iron metabolism, has attracted enormous attention due to its important role in the pathogenesis of ACD. This article reviews the research progress on the role and underlying regulatory mechanisms of hepcidin in ACD. We also discuss the potential of hepcidin as an effective therapeutic target for ACD treatment, in order to provide a new maneuver for improving the quality of ACD patients' life.
